Tandem Diabetes (TNDM) Q1 2026 earnings review
Margin Expansion Validates Strategic Pivot, Despite Top-Line Deceleration
Tandem's Q1 results reflect a company undergoing a massive, deliberate business model transition. Reported worldwide sales grew just 5% to $247.2M, decelerating from 2025's double-digit pace. However, this top-line optical slowdown is a direct result of the shift to the 'pay-as-you-go' (PayGo) pharmacy model, which foregoes upfront pump revenue in exchange for recurring, higher-margin supply sales. The underlying unit economics prove the strategy is working: Gross margins accelerated 480 basis points to 55%, and Adjusted EBITDA reversed from a massive Q1 25 deficit to a positive $2.7M. International markets are facing transitional headwinds, but the reaffirmed full-year guidance confirms management's confidence in their 2026 transformational targets.
🐂 Bull Case
Gross margin expanded to 55% from 51% a year ago. Adjusted EBITDA margin reversed from -34% in 25Q1 to +1% in 26Q1. The shift to higher-ASP pharmacy channels and lower manufacturing costs for the Mobi pump are driving durable margin acceleration.
Despite the accounting headwinds of the PayGo transition, U.S. pump shipments grew to 19,000 (up from 17,000 in Q1 2025), driving a solid 7% U.S. revenue increase.
🐻 Bear Case
International sales grew a meager 3% as reported, but decelerated to negative 5% in constant currency. Pump shipments outside the U.S. dropped to 10,000 from 11,000 a year ago, hindered by distributor destocking.
The strategic shift to PayGo creates an estimated $85M-$95M reported revenue headwind for FY26. Until the recurring supply revenue fully scales, headline growth rates will look artificially depressed.
⚖️ Verdict: 🟢
Bullish. Management is executing exactly what they promised in late 2025: sacrificing near-term recognized revenue for a vastly superior, recurring-margin profile. The 480 bps gross margin jump proves the unit economics of the pharmacy channel work.
Key Themes
Pay-As-You-Go (PayGo) Pharmacy Model is Live
Tandem officially launched its PayGo reimbursement model in the U.S. pharmacy channel this quarter. By eliminating the massive upfront costs for patients (traditionally handled via DME channels), Tandem expects to drive higher lifetime value and recurring supply purchases. This shift is already manifesting in the financials: it depressed U.S. top-line growth (up 7%) but accelerated overall gross margins to 55%.
International Transition Weighs Heavily
International sales decreased 5% in constant currency, and international pump shipments fell to ~10,000 from ~11,000 in the prior year. This deceleration is largely tied to a multi-year strategy to transition from third-party distributors to direct commercial operations in key European markets. While direct operations command ~30% higher ASPs, the immediate impact is distributor destocking and buybacks, hurting near-term volumes.
Mobi Ecosystem Expansion Continues
Tandem expanded the Mobi connected care ecosystem by adding Android compatibility, removing a significant adoption barrier for non-iOS users. The broader adoption of the Mobi pump (which is 10-15% cheaper to manufacture than the t:slim) is a crucial secondary driver of the company's gross margin acceleration.
Constant Currency vs Reported Growth Divergence
Macro currency effects are providing an optical lift. Worldwide sales increased 5% as reported, but only 2% in constant currency. For international specifically, a 3% reported gain masks a 5% organic contraction. As the company expands direct European operations, FX exposure will become a more prominent variable.
Other KPIs
Reversing. FCF turned positive, a massive improvement from the $(21.2)M burn in 25Q1. Operating cash flow generated $11.1M, easily funding $6.3M in capital expenditures. This validates management's commitment to self-funding its transformation.
Decelerating significantly from $239.3M in 25Q1. While last year's figure was inflated by a $75.2M acquired IPR&D charge and $11.2M in restructuring, core run-rate expenses (R&D and SG&A) were held flat to slightly down year-over-year, indicating strong operational leverage as the company scales.
Guidance
Stable. The reaffirmed guidance implies ~6% YoY growth at the midpoint. This represents a deceleration from historical double-digit growth, but explicitly bakes in an estimated $85M-$95M headwind from the shift to the PayGo pharmacy model and international direct transitions. Given the solid Q1, achievement is highly likely.
Accelerating. Reaffirmed guidance implies a step up from FY25's 54%. The Q1 result of 55% shows the company is well on pace, driven by higher-priced pharmacy supply sales and manufacturing efficiencies from the Mobi platform.
Reversing. After posting negative adjusted EBITDA for FY25, the company targets 5-6% for FY26. With Q1 already achieving 1% (despite Q1 typically being the weakest seasonal quarter due to deductible resets), the company is on a clear trajectory to meet this target.
Key Questions
PayGo Adoption Rates
With the PayGo model now live, what percentage of Q1 U.S. pump shipments went through the pharmacy channel vs traditional DME, and how does that compare to your internal targets for the year?
International Destocking Visibility
International constant currency sales fell 5%. Do you have clear visibility into channel inventory levels, and at what point in the year do you expect international shipments to trough before the direct operations take over?
Mobi Tubeless Timeline
In prior quarters, a 2026 launch of the Mobi Tubeless patch pump was teased. Has the FDA 510(k) submission been officially filed, and are you still on track for a second-half commercial launch?